SUBJECTS : Pharmacotherapy | Real-world Medicine | Disease Management | Drugs | Health Economics | Health Outcome
LATEST MANUSCRIPTS IN Drugs in Context
- Andrea De Giglio, Biagio Ricciuti, Giulio Metro. The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks. Drugs in context. 2023, 12:
Cited : 1Read More - Retno S Wardani, Natalie Schellack, Tamlyn Govender, Abhay N Dhulap, Prapti Utami, Vinod Malve, Yong Chiat Wong. Treatment of the common cold with herbs used in Ayurveda and Jamu: monograph review and the science of ginger, liquorice, turmeric and peppermint. Drugs in context. 2023, 12: Cited : 4Read More
- Mikhail Kostinov, Oksana Svitich, Alexander Chuchalin, Natalya Abramova, Valery Osiptsov, Ekaterina Khromova, Dmitry Pakhomov, Vitaly Tatevosov, Anna Vlasenko, Vilia Gainitdinova, Kirill Mashilov, Nadezhda Kryukova, Irina Baranova, Anton Kostinov. Changes in nasal, pharyngeal and salivary secretory IgA levels in patients with COVID-19 and the possibility of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms. Drugs in context. 2023, 12: Cited : 2Read More
- Yeong Yeh Lee, Vincent Tee. Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report. Drugs in context. 2023, 12: Cited : 1Read More
- Barbara Moroni, Veronika Óvári, Cristina Nicastro, Raffaella de Salvo, Andreas Ehret. A real-world evidence study evaluating consumer experience of Supradyn Recharge or Supradyn Magnesium and Potassium during demanding periods. Drugs in context. 2023, 12: Cited : 0Read More
- Yeong Yeh Lee, Vincent Tee. Hepatoprotective effects of silymarin in management of liver injury caused by tuberculosis treatment. Drugs in context. 2023, 12: Cited : 1Read More
- Ahmed Hashem. Silymarin and management of liver function in non-alcoholic steatohepatitis: a case report. Drugs in context. 2023, 12: Cited : 0Read More
- Timothy C Hardman, Rob Aitchison, Richard Scaife, Jean Edwards, Gill Slater. The future of clinical trials and drug development: 2050. Drugs in context. 2023, 12: Cited : 6Read More
- Andrew Merker, Kartik Anne, Justin Rayyan, Milena Murray. Necessity of vancomycin trough concentrations to manage uncomplicated acute bacterial skin and skin structure infections: a laboratory stewardship analysis. Drugs in context. 2023, 12: Cited : 0Read More
- Virginia Bellido, Cristóbal Morales, Araceli Muñoz Garach, José Manuel García Almeida, Juan Luis Fernández Morera, Beatriz González Aguilera, Martín López de la Torre, Diego Bellido. Descriptive study of a clinical and educational telemedicine intervention in patients with diabetes receiving glargine 300 U/ml (Toujeo) in Spain: results of the T-Coach programme. Drugs in context. 2023, 12: Cited : 1Read More
- Yeong Yeh Lee, Vincent Tee. Management of non-alcoholic fatty liver disease incidentally detected during other medical assessments. Drugs in context. 2023, 12: Cited : 0Read More
- Giorgia Guaitoli, Lodovica Zullo, Marcello Tiseo, Matthew Dankner, April An Rose, Francesco Facchinetti. Non-small-cell lung cancer: how to manage -mutated disease. Drugs in context. 2023, 12: Cited : 10Read More
- Ana Martins, Ana Maria Lé, Tiago Torres. Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far. Drugs in context. 2023, 12: Cited : 3Read More
- Barbara Tagliaferri, Ludovica Mollica, Raffella Palumbo, Claudia Leli, Alberto Malovini, Matteo Terzaghi, Erica Quaquarini, Cristina Teragni, Stefano Maccarone, Andrea Premoli, Federico Sottotetti. Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR/HER2 breast cancer treated with CDK4/6 inhibitors and endocrine therapy. Drugs in context. 2023, 12: Cited : 0Read More
- Tanyaporn Chantarojanasiri. Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report. Drugs in context. 2023, 12: Cited : 1Read More
